KarenKuhnBallenMD

Oncology • Falls Church, VA

Hematologic Oncology

Professor of Medicine, UVA School of Medicine and Section Chief, Hematologic Malignancies and Stem Cell Transplants

Join to view full profile

Dr. Ballen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ballen's full profile

Already have an account?

Office
3300 Gallows Rd
Falls Church, VA 22042
Phone+1 571-423-5699

Fax+1 617-724-1126

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1989 - 1992
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1986 - 1989
Geisel School of Medicine at DartmouthClass of 1986

Certifications & Licensure

VA State Medical License 2016 - 2026
MA State Medical License 1989 - 2018
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2014
Boston Magazine Castle Connolly, 2011-2013
America's Top Doctors for Cancer Castle Connolly, 2011-2013

Clinical Trials

Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus Start of enrollment: 2005 Aug 01
Completed
Phase 2
Study of Velcade and Thalidomide in Patients With Myelodysplasia Start of enrollment: 2005 Jun 01
Terminated
Phase 1
Phase I Study of Sequential Cord Blood Transplants Start of enrollment: 2003 May 01
Completed
Phase 1
Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization. Start of enrollment: 2004 Jul 01
Completed
Phase 1
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Start of enrollment: 2006 Sep 01
Terminated
Phase 2
A Phase II Study of Parathyroid Hormone Following Sequential Unrelated Cord Blood Transplant Start of enrollment: 2006 Sep 01
A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia Start of enrollment: 2007 Nov 01
Completed
Phase 1
Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia Start of enrollment: 2008 Jun 01
Unknown status
Phase 1, Phase 2
Treatment of Older Adults With Acute Lymphoblastic Leukemia Start of enrollment: 2009 Aug 01
Completed
Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Reduced Intensity Double Umbilical Cord Blood Transplantation Start of enrollment: 2011 Dec 01
Completed
Phase 2
Double Cord Versus Haploidentical (BMT CTN 1101) Start of enrollment: 2012 Jun 01
Completed
Phase 3
The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies. Start of enrollment: 2012 Jul 01
Terminated
Phase 2
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation Start of enrollment: 2012 Feb 01
Recruiting
Phase 2
Lenalidomide Plus Chemotherapy for AML Start of enrollment: 2012 Sep 01
Completed
Phase 1
Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults Start of enrollment: 2014 Dec 01
Completed
Phase 1
Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS Start of enrollment: 2020 Aug 19
Recruiting
Phase 2
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis Start of enrollment: 2023 Dec 08
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

198 citations
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
Lori Muffly, Marcelo C. Pasquini, Michael Martens, Ruta Brazauskas, Xiaochun Zhu
Blood. 2017-08-31
23 citations
Alisertib Plus Induction Chemotherapy in Previously Untreated Patients With High-Risk, Acute Myeloid Leukaemia: A Single-Arm, Phase 2 Trial
Andrew M. Brunner, Traci M. Blonquist, Daniel J. DeAngelo, Malgorzata McMasters, Geoffrey Fell
The Lancet. Haematology. 2020-02-01
191 citations
Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloi...
Yi Bin Chen, Shuli Li, Andrew A. Lane, Christine Connolly, Candice Del Rio
Biology of Blood and Marrow Transplantation. 2014-12-01

Journal Articles

The European Society for Blood and Marrow Transplantation (EBMT) Consensus Recommendations for Donor Selection in Haploidentical Hematopoietic Cell Transplantation
Leo Luznik, Karen Ballen, Asad Bashey, Hillard M Lazarus, Bipin N Savani, Rizwan Romee, Ephraim J Fuchs, Nature

Abstracts/Posters

Development of HHV-6-Specific Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of CD4+ T Cells
Karen K. Ballen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Blockade of IL-15 Utilizing Bnz-1, a Selective _-Chain Inhibiting Peptide, Is Safe and Has Clinical Activity in Patients with T-Cell Large Granular Lymphocytic Leukemi...
Karen Ballen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Distance Does Not Matter: Excellent Survival Outcomes for Leukemia Patients in Rural Appalachia
Karen K. Ballen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Lost to Follow-up Rates Are Higher in Pediatric Than Adult Survivors, but Not By Transplant Type: A Report from the Center for International Blood and Marrow Transplan...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Mye...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Overall Survival Improving for Umbilical Cord Blood TransplantOctober 8th, 2024
Umbilical Cord Blood Transplants Improve Cancer Survival Rates in All RacesOctober 2nd, 2024
Survival Gap Eliminated for Black Cord Blood Recipients with Blood Cancers, Study FindsOctober 1st, 2024
Join now to see all